Incomplete Reversibility of Tenofovir-Related Renal Toxicity in HIV-Infected Men

被引:92
作者
Wever, Karen [1 ,2 ,3 ]
van Agtmael, Michiel A. [3 ]
Carr, Andrew [1 ,2 ]
机构
[1] St Vincents Hosp, HIV Immunol & Infect Dis Unit, Sydney, NSW 2010, Australia
[2] St Vincents Hosp, Ctr Appl Med Res, Sydney, NSW 2010, Australia
[3] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands
关键词
antiretroviral therapy; renal toxicity; reversibility; tenofovir; DISOPROXIL FUMARATE; FANCONI-SYNDROME; NEPHROTOXICITY; DISEASE; SAFETY; THERAPY; FAILURE; DF;
D O I
10.1097/QAI.0b013e3181d05579
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Significant nephrotoxicity develops in 1%-2% of HIV-infected adults receiving tenofovir (TDF). This nephrotoxicity is said to resolve rapidly, but this assessment is based on short follow-up, very few patients and use of serum creatinine, an insensitive measure of renal function. Methods: We determined the reversibility of TDF-related nephrotoxicity in 24 HIV-infected male outpatients who ceased TDF for renal impairment by retrospective assessment of estimated glomerular filtration rate (eGFR) using the Modified Diet in Renal Disease equation. Results: Median (interquartile range) eGFR pre-TDF was 74 (6188) mL.min(-1) . 1.73 m(-2), fell to 51 (39-61) mL.min(-1) . 1.73 m(-2) at TDF cessation and increased to 58 (48-70) mL.min(-1) . 1.73 m(-2) a median 13 months after TDF cessation (most recent vs pre-TDF eGFR; P = 0.0008). Results were similar with the Cockcroft-Gault equation and after exclusion of patients who had shorter follow-up after TDF cessation. Only 10 (42%) patients reached their pre-TDF eGFR. Greater eGFR improvement was significantly associated with more rapid decline in eGFR on TDF therapy and in those who received TDF with a protease inhibitor, with a trend for shorter duration of TDF therapy. Discussion: In this population, TDF-related renal toxicity was not always fully reversible.
引用
收藏
页码:78 / 81
页数:4
相关论文
共 31 条
  • [1] [Anonymous], 13 C RETR OPP INF DE
  • [2] [Anonymous], 2008, DEP HLTH HUMAN SERVI, P1
  • [3] [Anonymous], 2008, Am J Kidney Dis, V51, pS1
  • [4] CRANE H, 2006, 13 C RETR OPP INF DE
  • [5] DAVIES C, 2006, 8 C DRUG THER HIV IN
  • [6] A population-based study of the incidence and outcomes of diagnosed chronic kidney disease
    Drey, N
    Roderick, P
    Mullee, M
    Rogerson, M
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 42 (04) : 677 - 684
  • [7] Renal disease in patients with HIV infection - Epidemiology, pathogenesis and management
    Fine, Derek M.
    Perazella, Mark A.
    Lucas, Gregory M.
    Atta, Mohamed G.
    [J]. DRUGS, 2008, 68 (07) : 963 - 980
  • [8] Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV
    Gallant, JE
    DeJesus, E
    Arribas, JR
    Pozniak, AL
    Gazzard, B
    Campo, RE
    Lu, B
    McColl, D
    Chuck, S
    Enejosa, J
    Toole, JJ
    Cheng, AK
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (03) : 251 - 260
  • [9] Efficacy and safety of tenofovir DF vs stavuldine in combination therapy in antiretroviral-naive patients - A 3-year randomized trial
    Gallant, JE
    Staszewski, S
    Pozniak, AL
    DeJesus, E
    Suleiman, JMAH
    Miller, MD
    Coakley, DF
    Lu, B
    Toole, JJ
    Cheng, AK
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (02): : 191 - 201
  • [10] GUEST J, 2006, 13 C RETR OPP INF DE